Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose versus very low-dose mydriatic microdrops for retinopathy of prematurity eye examinations
ACTRN12619000795190Phase 4Completed
- Sponsor
- University of Otago
- Start
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of phenylephrine and cyclopentolate in retinopathy of prematurity (ROP) (2 arms), sponsored by University of Otago. Primary endpoint: Ease of dilation / ease of retinopathy examination. Started Oct 2019; status: completed.
02
Drugs
phenylephrinecyclopentolate
03
Conditions
retinopathy of prematurity (ROP)
Beyond the preview
Go deeper on ACTRN12619000795190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12619000795190.